Ephedra

DB01363ApprovedNutraceuticalOrganism Based TherapiesAlpha-and Beta-adrenergic AgonistsSympathomimetic (Adrenergic) Agents

Ephedra is an alpha and beta-adrenergic agonist used for the management of respiratory conditions related to bronchial asthma, such as wheezing, shortness of breath, and tightness of chest. Ephedra is an alkaloid chemical compound traditionally obtained from the plant Ephedra sinica.

Mechanism
Curator reviewed
Primary indication
Ephedra is indicated for the temporary relief of shortness of breath, tightness of chest, and wheezing due to bronchial asthma.Curator reviewed
First approval
Canada, 1999
Also known as
Cao ma huang root · Chinese ephedra root (ephedra sinica) · Chinese jointfir · Ephedra ma-huang root · Ephedra root (ephedra sinica)

Resolves to

What you can answer from here — as of October 02, 2026

13Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
891Drug interactionsStructured to mechanism, not free text
Sign in
2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
26Marketed productsAcross 1 country and 22 labellers
Sign in
38+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Ephedra, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account